⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090352 | 0.82 | DYRK1A (0.34) | — | |
| SCHEMBL29941895 | 0.80 | — | — | |
| SCHEMBL10335890 | 0.78 | — | — | |
| SCHEMBL27635298 | 0.78 | — | — | |
| SCHEMBL17804439 | 0.78 | — | — | |
| SCHEMBL10335896 | 0.78 | ADORA2A (0.33) | — | |
| SCHEMBL27613378 | 0.78 | ADORA2A (0.33) | — | |
| SCHEMBL9015496 | 0.76 | ADORA2A (0.33) | — | |
| SCHEMBL14817198 | 0.75 | DYRK1A (0.34) | — | |
| SCHEMBL18114359 | 0.75 | DYRK1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844376-B2 | Structurally-enhanced miRNA inhibitor S-TuD | UNIVERSITY OF TOKYO (JP) | 2020-11-24 | — | — | US | claimed |
| US-20180223281-A1 | STRUCTURALLY-ENHANCED miRNA INHIBITOR S-TuD | THE UNIVERSITY OF TOKYO (JP) | 2018-08-09 | — | — | US | claimed |
| EP-3351632-A1 | STRUCTURALLY-ENHANCED miRNA INHIBITOR S-TUD | The University Of Tokyo (JP) | 2018-07-25 | — | — | EP | claimed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | claimed |
| EP-0365556-A1 | NUCLEOSIDE ANALOGUES. | GENENTECH INC (US) | 1990-05-02 | — | — | EP | claimed |
| WO-1988009796-A1 | NUCLEOSIDE ANALOGUES | GENENTECH, INC. (US) | 1988-12-15 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021046426-A9 | CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES | SPEROVIE BIOSCIENCES, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | disclosed |
| EP-0365556-A1 | NUCLEOSIDE ANALOGUES. | GENENTECH INC (US) | 1990-05-02 | — | — | EP | disclosed |
| WO-1988009796-A1 | NUCLEOSIDE ANALOGUES | GENENTECH, INC. (US) | 1988-12-15 | — | — | WO | disclosed |